医学
心脏再同步化治疗
射血分数
内科学
危险系数
心脏病学
心力衰竭
左束支阻滞
QRS波群
临床终点
束支阻滞
置信区间
心电图
随机对照试验
作者
Pugazhendhi Vijayaraman,Dipen Zalavadia,Abdul Haseeb,Cicely Dye,Nidhi Madan,Jamario Skeete,Sharath C. Vipparthy,W. Glenn Young,Venkatesh Ravi,Clement Rajakumar,Parash Pokharel,Timothy R. Larsen,Henry D. Huang,Randle Storm,Jess W. Oren,Syeda Atiqa Batul,Richard G. Trohman,Faiz A. Subzposh,Parikshit S. Sharma
出处
期刊:Heart Rhythm
[Elsevier]
日期:2022-04-29
卷期号:19 (8): 1263-1271
被引量:106
标识
DOI:10.1016/j.hrthm.2022.04.023
摘要
Background Cardiac resynchronization therapy (CRT) with biventricular pacing (BVP) is well-established therapy in patients with reduced left ventricular ejection fraction (LVEF) and bundle branch block or indication for pacing. Conduction system pacing (CSP) using His-bundle pacing (HBP) or left bundle branch area pacing (LBBAP) has been shown to be a safe and more physiological alternative to BVP. Objective The purpose of this study was to compare the clinical outcomes between CSP and BVP among patients undergoing CRT. Methods This observational study included consecutive patients with LVEF ≤35% and class I or II indications for CRT who underwent successful BVP or CSP at 2 major health care systems. The primary outcome was the composite endpoint of time to death or heart failure hospitalization (HFH). Secondary outcomes included subgroup analysis in left bundle branch block as well as individual endpoints of death and HFH. Results A total of 477 patients (32% female) met inclusion criteria (BVP 219; CSP 258 [HBP 87, LBBAP 171]). Mean age was 72 ± 12 years, and mean LVEF was 26% ± 6%. Comorbidities included hypertension 70%, diabetes mellitus 45%, and coronary artery disease 52%. Paced QRS duration in CSP was significantly narrower than BVP (133 ± 21 ms vs 153 ± 24 ms; P <.001). LVEF improved in both groups during mean follow-up of 27 ± 12 months and was greater after CSP compared to BVP (39.7% ± 13% vs 33.1% ± 12%; P <.001). Primary outcome of death or HFH was significantly lower with CSP vs BVP (28.3% vs 38.4%; hazard ratio 1.52; 95% confidence interval 1.082–2.087; P = .013). Conclusion CSP improved clinical outcomes compared to BVP in this large cohort of patients with indications for CRT. Cardiac resynchronization therapy (CRT) with biventricular pacing (BVP) is well-established therapy in patients with reduced left ventricular ejection fraction (LVEF) and bundle branch block or indication for pacing. Conduction system pacing (CSP) using His-bundle pacing (HBP) or left bundle branch area pacing (LBBAP) has been shown to be a safe and more physiological alternative to BVP. The purpose of this study was to compare the clinical outcomes between CSP and BVP among patients undergoing CRT. This observational study included consecutive patients with LVEF ≤35% and class I or II indications for CRT who underwent successful BVP or CSP at 2 major health care systems. The primary outcome was the composite endpoint of time to death or heart failure hospitalization (HFH). Secondary outcomes included subgroup analysis in left bundle branch block as well as individual endpoints of death and HFH. A total of 477 patients (32% female) met inclusion criteria (BVP 219; CSP 258 [HBP 87, LBBAP 171]). Mean age was 72 ± 12 years, and mean LVEF was 26% ± 6%. Comorbidities included hypertension 70%, diabetes mellitus 45%, and coronary artery disease 52%. Paced QRS duration in CSP was significantly narrower than BVP (133 ± 21 ms vs 153 ± 24 ms; P <.001). LVEF improved in both groups during mean follow-up of 27 ± 12 months and was greater after CSP compared to BVP (39.7% ± 13% vs 33.1% ± 12%; P <.001). Primary outcome of death or HFH was significantly lower with CSP vs BVP (28.3% vs 38.4%; hazard ratio 1.52; 95% confidence interval 1.082–2.087; P = .013). CSP improved clinical outcomes compared to BVP in this large cohort of patients with indications for CRT.
科研通智能强力驱动
Strongly Powered by AbleSci AI